San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug sector in February following revealing promising data from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection As well as in Ma